NEXPOVIO Film-coated tablet Ref.[116825] Active ingredients: Selinexor

Source: European Medicines Agency (EU)  Revision Year: 2026  Publisher: Stemline Therapeutics B.V., Basisweg 10, 1043 AP Amsterdam, Netherlands

Product name and form

NEXPOVIO 20 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Blue, round, bi-convex, film-coated tablet (4 mm thick and 7 mm in diameter) with "K20" debossed on one side.

Qualitative and quantitative composition

Each film-coated tablet contains 20 mg of selinexor.

For the full list of excipients, see section 6.1.

Active Ingredient

Selinexor is a reversible covalent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). XPO1 is the major mediator of the nuclear export of many cargo proteins including tumour suppressor proteins (TSPs), growth regulators and mRNAs of growth promoting (oncogenic) proteins. XPO1 inhibition by selinexor leads to marked accumulation of TSPs in the nucleus, cell cycle arrest, reductions in several oncoproteins such as c-Myc and cyclin D1, and apoptosis of cancer cells.

List of Excipients

Tablet core:

Microcrystalline cellulose (pH-101) (E460i)
Croscarmellose sodium (E468)
Povidone K30 (E1201)
Colloidal silicon dioxide (E551)
Magnesium stearate (E470b)
Microcrystalline cellulose (PH-102) (E460i)
Sodium lauryl sulphate (E514i)

Tablet coating:

Talc (E553b)
Poly(vinyl alcohol) partially hydrolysed (E1203)
Glyceryl monostearate (E471)
Polysorbate 80 (E433)
Titanium dioxide (E171)
Macrogol (E1521)
Indigo carmine aluminium lake (E132)
Brilliant blue FCF aluminium lake (E133)

Pack sizes and marketing

PVC/PCTFE/PVC-aluminium blisters containing 2, 3, 4, 5 or 8 film-coated tablets.

One outer carton contains four child resistant inner cartons, each with one blister. Cartons contain a total of 8, 12, 16, 20 or 32 film-coated tablets. Not all pack-sizes may be marketed.

Marketing authorization holder

Stemline Therapeutics B.V., Basisweg 10, 1043 AP Amsterdam, Netherlands

Marketing authorization dates and numbers

EU/1/21/1537/005
EU/1/21/1537/001
EU/1/21/1537/002
EU/1/21/1537/003
EU/1/21/1537/004

Date of first authorisation: 26 March 2021
Date of latest renewal: 13 May 2022

Drugs

Drug Countries
NEXPOVIO Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.